|
1
|
Harris EER: Precision medicine for breast
cancer: The paths to truly individualized diagnosis and treatment.
Int J Breast Cancer. 2018(4809183)2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sarhangi N, Hajjari S, Heydari SF,
Ganjizadeh M, Rouhollah F and Hasanzad M: Breast cancer in the era
of precision medicine. Mol Biol Rep. 49:10023–10037.
2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Arnold M, Morgan E, Rumgay H, Mafra A,
Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S
and Soerjomataram I: Current and future burden of breast cancer:
Global statistics for 2020 and 2040. Breast. 66:15–23.
2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mavrommati I, Johnson F, Echeverria GV and
Natrajan R: Subclonal heterogeneity and evolution in breast cancer.
NPJ Breast Cancer. 7(155)2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Singh DN, Daripelli S, Elamin Bushara MO,
Polevoy GG and Prasanna M: Genetic testing for successful cancer
treatment. Cureus. 15(e49889)2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Orrantia-Borunda E, Anchondo-Nuñez P,
Acuña-Aguilar LE, Gómez-Valles FO and Ramírez-Valdespino CA:
Subtypes of breast cancer. In: Breast Cancer [Internet]. Mayrovitz
HN (ed). Exon Publications, Brisbane, AU, 2022.
|
|
7
|
Damaskos C, Garmpis N, Garmpi A,
Nikolettos K, Sarantis P, Georgakopoulou VE, Nonni A, Schizas D,
Antoniou EA, Karamouzis MV, et al: Investigational drug treatments
for triple-negative breast cancer. J Pers Med.
11(652)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Papalexis P, Georgakopoulou VE, Keramydas
D, Vogiatzis R, Taskou C, Anagnostopoulou FA, Nonni A, Lazaris AC,
Zografos GC, Kavantzas N and Thomopoulou GE: Clinical,
histopathological, and immunohistochemical characteristics of
predictive biomarkers of breast cancer: A retrospective study.
Cancer Diagn Progn. 4:340–351. 2024.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Mercogliano MF, Bruni S, Mauro FL and
Schillaci R: Emerging targeted therapies for HER2-positive breast
cancer. Cancers (Basel). 15(1987)2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sebastian AM and Peter D: Artificial
intelligence in cancer research: Trends, challenges and future
directions. Life (Basel). 12(1991)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Adhit KK, Wanjari A, Menon S and K S:
Liquid biopsy: An evolving paradigm for non-invasive disease
diagnosis and monitoring in medicine. Cureus.
15(e50176)2023.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Feng Y, Spezia M, Huang S, Yuan C, Zeng Z,
Zhang L, Ji X, Liu W, Huang B, Luo W, et al: Breast cancer
development and progression: Risk factors, cancer stem cells,
signaling pathways, genomics, and molecular pathogenesis. Genes
Dis. 5:77–106. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Yersal O and Barutca S: Biological
subtypes of breast cancer: Prognostic and therapeutic implications.
World J Clin Oncol. 5:412–424. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Testa U, Castelli G and Pelosi E: Breast
cancer: A molecularly heterogenous disease needing subtype-specific
treatments. Med Sci (Basel). 8(18)2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zhao S, Zuo WJ, Shao ZM and Jiang YZ:
Molecular subtypes and precision treatment of triple-negative
breast cancer. Ann Transl Med. 8(499)2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Subhan MA, Parveen F, Shah H, Yalamarty
SSK, Ataide JA and Torchilin VP: Recent advances with precision
medicine treatment for breast cancer including triple-negative
sub-type. Cancers (Basel). 15(2204)2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Bettaieb A, Paul C, Plenchette S, Shan J,
Chouchane L and Ghiringhelli F: Precision medicine in breast
cancer: Reality or utopia? J Transl Med. 15(139)2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Patel A, Unni N and Peng Y: The changing
paradigm for the treatment of HER2-positive breast cancer. Cancers
(Basel). 12(2081)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ottaiano A, Ianniello M, Santorsola M,
Ruggiero R, Sirica R, Sabbatino F, Perri F, Cascella M, Di Marzo M,
Berretta M, et al: From chaos to opportunity: decoding cancer
heterogeneity for enhanced treatment strategies. Biology (Basel).
12(1183)2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wang Q, Shao X, Zhang Y, Zhu M, Wang FXC,
Mu J, Li J, Yao H and Chen K: Role of tumor microenvironment in
cancer progression and therapeutic strategy. Cancer Med.
12:11149–11165. 2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Olopade OI, Grushko TA, Nanda R and Huo D:
Advances in breast cancer: Pathways to personalized medicine. Clin
Cancer Res. 14:7988–7999. 2008.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Nelson HD, Huffman LH, Fu R, Harris EL,
Walker M and Bougatsos C: Genetic risk assessment and brca mutation
testing for breast and ovarian cancer susceptibility [Internet].
Rockville (MD): Agency for Healthcare Research and Quality (US);
2005.
|
|
23
|
Kinney AY, Simonsen SE, Baty BJ, Mandal D,
Neuhausen SL, Seggar K, Holubkov R and Smith K: Acceptance of
genetic testing for hereditary breast ovarian cancer among study
enrollees from an African American kindred. Am J Med Genet A.
140:813–826. 2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Mehrgou A and Akouchekian M: The
importance of BRCA1 and BRCA2 genes mutations in breast cancer
development. Med J Islam Repub Iran. 30(369)2016.PubMed/NCBI
|
|
25
|
Casaubon JT, Kashyap S and Regan JP: BRCA1
and BRCA2 mutations. [Updated 2023 Jul 23]. In: StatPearls
[Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
|
|
26
|
Maioru OV, Radoi VE, Coman MC, Hotinceanu
IA, Dan A, Eftenoiu AE, Burtavel LM, Bohiltea LC and Severin EM:
Developments in genetics: Better management of ovarian cancer
patients. Int J Mol Sci. 24(15987)2023.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Weitzel JN, Blazer KR, MacDonald DJ,
Culver JO and Offit K: Genetics, genomics, and cancer risk
assessment: State of the art and future directions in the era of
personalized medicine. CA Cancer J Clin. 61:327–359.
2011.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Mehmood S, Faheem M, Ismail H, Farhat SM,
Ali M, Younis S and Asghar MN: ‘Breast cancer resistance likelihood
and personalized treatment through integrated multiomics’. Front
Mol Biosci. 9(783494)2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wang RC and Wang Z: Precision medicine:
Disease subtyping and tailored treatment. Cancers (Basel).
15(3837)2023.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Eralp Y: The role of genomic profiling in
advanced breast cancer: The two faces of Janus. Transl
Oncogenomics. 8 (Suppl 1):S1–S7. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Masood S: Breast cancer subtypes:
Morphologic and biologic characterization. Womens Health (Lond).
12:103–119. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tariq M, Richard V and Kerin MJ: MicroRNAs
as molecular biomarkers for the characterization of basal-like
breast tumor subtype. Biomedicines. 11(3007)2023.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Iqbal N and Iqbal N: Human epidermal
growth factor receptor 2 (HER2) in cancers: Overexpression and
therapeutic implications. Mol Biol Int. 2014(852748)2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Krishnamurti U and Silverman JF: HER2 in
breast cancer: A review and update. Adv Anat Pathol. 21:100–107.
2014.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Dank M, Mühl D, Pölhös A, Csanda R, Herold
M, Kovacs AK, Madaras L, Kulka J, Palhazy T, Tokes AM, et al: The
prediction analysis of microarray 50 (PAM50) gene expression
classifier utilized in indeterminate-risk breast cancer patients in
hungary: A consecutive 5-year experience. Genes (Basel).
14(1708)2023.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Archer SG, Eliopoulos A, Spandidos D,
Barnes D, Ellis IO, Blamey RW, Nicholson RI and Robertson JF:
Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer
and response to first line hormonal therapy. Br J Cancer.
72:1259–1266. 1995.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Caan BJ, Sweeney C, Habel LA, Kwan ML,
Kroenke CH, Weltzien EK, Quesenberry CP Jr, Castillo A, Factor RE,
Kushi LH and Bernard PS: Intrinsic subtypes from the PAM50 gene
expression assay in a population-based breast cancer survivor
cohort: prognostication of short- and long-term outcomes. Cancer
Epidemiol Biomarkers Prev. 23:725–734. 2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Cho N: Molecular subtypes and imaging
phenotypes of breast cancer. Ultrasonography. 35:281–288.
2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
El-Deiry WS, Goldberg RM, Lenz HJ, Shields
AF, Gibney GT, Tan AR, Brown J, Eisenberg B, Heath EI, Phuphanich
S, et al: The current state of molecular testing in the treatment
of patients with solid tumors, 2019. CA Cancer J Clin. 69:305–343.
2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Masoud V and Pagès G: Targeted therapies
in breast cancer: New challenges to fight against resistance. World
J Clin Oncol. 8:120–134. 2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Jallah JK, Dweh TJ, Anjankar A and Palma
O: A Review of the advancements in targeted therapies for breast
cancer. Cureus. 15(e47847)2023.PubMed/NCBI View Article : Google Scholar
|
|
42
|
El Sayed R, El Jamal L, El Iskandarani S,
Kort J, Abdel Salam M and Assi H: Endocrine and targeted therapy
for hormone-receptor-positive, HER2-negative advanced breast
cancer: insights to sequencing treatment and overcoming resistance
based on clinical trials. Front Oncol. 9(510)2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Andrahennadi S, Sami A, Manna M, Pauls M
and Ahmed S: Current landscape of targeted therapy in hormone
receptor-positive and HER2-negative breast cancer. Curr Oncol.
28:1803–1822. 2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Nandy A, Gangopadhyay S and Mukhopadhyay
A: Individualizing breast cancer treatment-The dawn of personalized
medicine. Exp Cell Res. 320:1–11. 2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Hu ZI and McArthur HL: Immunotherapy in
breast cancer: The new frontier. Curr Breast Cancer Rep. 10:35–40.
2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Vasileiou M, Papageorgiou S and Nguyen NP:
Current advancements and future perspectives of immunotherapy in
breast cancer treatment. Immuno. 3:195–216. 2023.
|
|
47
|
Lao Y, Shen D, Zhang W, He R and Jiang M:
Immune checkpoint inhibitors in cancer therapy-how to overcome drug
resistance? Cancers (Basel). 14(3575)2022.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Abdou Y, Goudarzi A, Yu JX, Upadhaya S,
Vincent B and Carey LA: Immunotherapy in triple negative breast
cancer: Beyond checkpoint inhibitors. NPJ Breast Cancer.
8(121)2022.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J,
Zhang Z, Qiu P and Gu X: Advances in immunotherapy for
triple-negative breast cancer. Mol Cancer. 22(145)2023.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Ayoub NM, Al-Shami KM and Yaghan RJ:
Immunotherapy for HER2-positive breast cancer: Recent advances and
combination therapeutic approaches. Breast Cancer (Dove Med Press).
11:53–69. 2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Debien V, De Caluwé A, Wang X,
Piccart-Gebhart M, Tuohy VK, Romano E and Buisseret L:
Immunotherapy in breast cancer: An overview of current strategies
and perspectives. NPJ Breast Cancer. 9(7)2023.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Chen N, Higashiyama N and Hoyos V:
Predictive biomarkers of immune checkpoint inhibitor response in
breast cancer: Looking beyond tumoral PD-L1. Biomedicines.
9(1863)2021.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Kossai M, Radosevic-Robin N and
Penault-Llorca F: Refining patient selection for breast cancer
immunotherapy: Beyond PD-L1. ESMO Open. 6(100257)2021.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Pasic MD, Samaan S and Yousef GM: Genomic
medicine: New frontiers and new challenges. Clin Chem. 59:158–167.
2013.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Di Sario G, Rossella V, Famulari ES,
Maurizio A, Lazarevic D, Giannese F and Felici C: Enhancing
clinical potential of liquid biopsy through a multi-omic approach:
A systematic review. Front Genet. 14(1152470)2023.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Panahiazar M, Chen N, Lituiev D and Hadley
D: Empowering study of breast cancer data with application of
artificial intelligence technology: Promises, challenges, and use
cases. Clin Exp Metastasis. 39:249–254. 2022.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Xu Y, Liu X, Cao X, Huang C, Liu E, Qian
S, Liu X, Wu Y, Dong F, Qiu CW, et al: Artificial intelligence: A
powerful paradigm for scientific research. Innovation (Camb).
2(100179)2021.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Dembrower K, Crippa A, Colón E, Eklund M
and Strand F: ScreenTrustCAD Trial Consortium. Artificial
intelligence for breast cancer detection in screening mammography
in Sweden: A prospective, population-based, paired-reader,
non-inferiority study. Lancet Digit Health. 5:e703–e711.
2023.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Roelands J, Mall R, Almeer H, Thomas R,
Mohamed MG, Bedri S, Al-Bader SB, Junejo K, Ziv E, Sayaman RW, et
al: Ancestry-associated transcriptomic profiles of breast cancer in
patients of African, Arab, and European ancestry. NPJ Breast
Cancer. 7(10)2021.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Johnson KB, Wei WQ, Weeraratne D, Frisse
ME, Misulis K, Rhee K, Zhao J and Snowdon JL: Precision medicine,
ai, and the future of personalized health care. Clin Transl Sci.
14:86–93. 2021.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Karachaliou N, Mayo-de-Las-Casas C,
Molina-Vila MA and Rosell R: Real-time liquid biopsies become a
reality in cancer treatment. Ann Transl Med. 3(36)2015.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Finotti A, Allegretti M, Gasparello J,
Giacomini P, Spandidos DA, Spoto G and Gambari R: Liquid biopsy and
PCR-free ultrasensitive detection systems in oncology (review). Int
J Oncol. 53:1395–1434. 2018.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Noor J, Chaudhry A, Noor R and Batool S:
Advancements and applications of liquid biopsies in oncology: A
narrative review. Cureus. 15(e42731)2023.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Shegekar T, Vodithala S and Juganavar A:
The emerging role of liquid biopsies in revolutionising cancer
diagnosis and therapy. Cureus. 15(e43650)2023.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Lone SN, Nisar S, Masoodi T, Singh M,
Rizwan A, Hashem S, El-Rifai W, Bedognetti D, Batra SK, Haris M, et
al: Liquid biopsy: A step closer to transform diagnosis, prognosis
and future of cancer treatments. Mol Cancer. 21(79)2022.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Tay TKY and Tan PH: Liquid biopsy in
breast cancer: A focused review. Arch Pathol Lab Med. 145:678–686.
2021.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Mazzitelli C, Santini D, Corradini AG,
Zamagni C, Trerè D, Montanaro L and Taffurelli M: Liquid biopsy in
the management of breast cancer patients: Where are we now and
where are we going. Diagnostics (Basel). 13(1241)2023.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Mithraprabhu S, Chen M, Savvidou I, Reale
A and Spencer A: Liquid biopsy: An evolving paradigm for the
biological characterisation of plasma cell disorders. Leukemia.
35:2771–2783. 2021.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Christofyllakis K, Bittenbring JT, Thurner
L, Ahlgrimm M, Stilgenbauer S, Bewarder M and Kaddu-Mulindwa D:
Cost-effectiveness of precision cancer medicine-current challenges
in the use of next generation sequencing for comprehensive tumour
genomic profiling and the role of clinical utility frameworks
(review). Mol Clin Oncol. 16(21)2022.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Pashayan N, Antoniou AC, Ivanus U,
Esserman LJ, Easton DF, French D, Sroczynski G, Hall P, Cuzick J,
Evans DG, et al: Personalized early detection and prevention of
breast cancer: ENVISION consensus statement. Nat Rev Clin Oncol.
17:687–705. 2020.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Demetriou D, Lockhat Z, Brzozowski L,
Saini KS, Dlamini Z and Hull R: The convergence of radiology and
genomics: Advancing breast cancer diagnosis with radiogenomics.
Cancers (Basel). 16(1076)2024.PubMed/NCBI View Article : Google Scholar
|
